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Immunity to common bacteria requires the generation of antibodies that promote 
opsonophagocytosis and neutralise toxins. Pooled human immunoglobulin is widely advocated as 
an adjunctive treatment for clinical Streptococcus pyogenes infection however, the protein targets 
of the reagent remain ill defined. Affinity purification of the anti-streptococcal antibodies present 
within pooled immunoglobulin resulted in the generation of an IgG preparation that promoted 
opsonophagocytic killing of S. pyogenes in vitro and provided passive immunity in vivo. Isolation 
of the streptococcal surface proteins recognised by pooled human immunoglobulin permitted 
identification and ranking of 94 protein antigens, ten of which were reproducibly identified across 
four contemporary invasive S. pyogenes serotypes (M1, M3, M12 and M89). The data provide novel 
insight into the action of pooled human immunoglobulin during invasive S. pyogenes infection, and 
demonstrate a potential route to enhance the efficacy of antibody based therapies.
Over the past 30 years there has been a steady rise in the global rate of severe Streptococcus pyogenes 
infection, which now exceeds 3 cases/100,000 in some regions1,2. The attendant morbidity and mortality 
of invasive S. pyogenes diseases such as necrotizing fasciitis are considerable, with a case fatality rate 
exceeding 40% in patients who develop streptococcal toxic shock syndrome2. Although the basis for 
population immunity to S. pyogenes is poorly understood, recent studies have indicated that adjunctive 
intravenous immunoglobulin therapy (IVIG) may confer a survival benefit during invasive S. pyogenes 
infection3–5.
IVIG is a commercially available plasmapheresis product that is purified from the blood of over one 
thousand healthy donors. While originally developed as a replacement therapy for hypogammaglobu-
linemia, the presence of specific antibodies to many human pathogens makes pooled immunoglobulin 
an effective prophylactic treatment for several infective conditions including hepatitis A, measles and 
rubella. Recent attention has focused on the protective activity of IVIG against a number of Gram pos-
itive pathogens, most notably S. pyogenes3–7.
Experimentally, IVIG has been shown to reduce systemic inflammation associated with streptococcal 
superantigen production and to promote opsonophagocytic clearance of S. pyogenes both in vitro, and in 
a humanised mouse model8,9. Clinically, one small trial and two population-based studies have reported 
benefits of IVIG administration during severe S. pyogenes infection and, although controversial, adjunct 
IVIG therapy is advocated by many physicians3–5. While some attention has focused on the varying 
ability of IVIG to neutralise streptococcal superantigens10, little is known about the S. pyogenes surface 
antigens recognised by IVIG and the mechanisms by which the reagent promotes bacterial clearance 
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remain ill defined. One study has demonstrated the presence of anti-M1 protein antibodies within com-
mercial preparations suggesting that IVIG may contain other antibodies that target major S. pyogenes 
surface proteins9. We sought to further characterise the S. pyogenes surface proteins recognised by IVIG 
and assess their protective efficacy using standard models of S. pyogenes infection.
Results
Purification of anti-streptococcal IgG from pooled immunoglobulin. The ability of IVIG to 
promote phagocytic uptake of S. pyogenes was first confirmed using a purified human neutrophil opsono-
phagocytosis assay. S. pyogenes strains were selected to represent four of the most common contemporary 
serotypes associated with invasive S. pyogenes infection in Europe and North America (M1, M3, M12 
and M89, Supplementary Table 1)1,2. At a fixed concentration of 5 mg/ml, IVIG was shown to promote 
neutrophil uptake of two representative strains from each serotype, all of which were isolated from inva-
sive disease manifestations or toxic shock cases (Fig. 1A). Although the M89 strain H395 is hyperencap-
sulated, neutrophil uptake was still promoted by IVIG, albeit to a lesser degree than the other isolates 
examined. Interestingly, the baseline uptake of the M3 strain H330 was markedly higher than the other 
strains selected for study, reducing the apparent effect of IVIG despite comparable levels of overall uptake 
occurring in the presence of the reagent. This confirms that the anti-streptococcal antibodies present 
within pooled immunoglobulin are capable of opsonising a range of S. pyogenes serotypes in vitro.
Having established the presence of opsonic anti-streptococcal antibodies within pooled immunoglob-
ulin, serotype M1 cell wall extract was covalently conjugated to cyanogen bromide activated agarose, 
and used to affinity purify the anti-streptococcal IgG fraction from commercially available IVIG. The 
reactivity of the resulting “enhanced” (E)-IVIG was then assessed by ELISA. The apparent affinity of 
E-IVIG for M1 S. pyogenes cell wall extract was shown to be much higher than that of the starting IVIG 
preparation (Fig. 1B). Furthermore, clear differences were observed in the binding of E-IVIG or IVIG to 
Figure 1. Preparation and properties of anti-streptococcal IgG (E-IVIG). (a) IVIG promotes neutrophil 
uptake of S. pyogenes. FITC labelled S. pyogenes cells were treated with 5 mg/ml of IVIG (black bars) or 
PBS (grey bars) and incubated with freshly isolated human neutrophils. Results from three independent 
experiments are expressed as percentage of FITC+ neutrophils (mean ± SD) after a 30 min co-incubation. 
n = 3, two-tailed t-test: p = 0.0003 (H364, H366 and H599); p = 0.0002; (H471); p = 0.0021 (H530); 
p < 0.0001 (H293); p = 0.0069 (H395). (b) Concentration-dependent binding of M1 S. pyogenes cell wall 
extract by E-IVIG (white triangles) and IVIG (black squares). (c) Serotype-independent binding of S. 
pyogenes cell wall extracts by E-IVIG (white bars) IVIG (black bars), at a fixed concentration (2500 ng/ml). 
Results from three independent experiments are expressed as triplicate A450 readings minus the background 
absorbance (mean ± SD). n = 3, two-tailed t-test, p < 0.0001 in all instances.
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cell wall extracts from each of the 20 isolates selected for study, suggesting that the apparent increase in 
affinity towards S. pyogenes was serotype independent (Fig. 1C).
Purification of S. pyogenes surface antigens by E-IVIG immunoprecipitation. In order to iden-
tify the streptococcal surface proteins targeted by IVIG, E-IVIG was covalently conjugated to cyano-
gen bromide activated agarose and used to purify the IVIG-reactive antigens from S. pyogenes cell wall 
extracts by immunoprecipitation. The resulting immunoprecipitates were visualised by immunoblot anal-
ysis; which confirmed the presence of a multitude of IVIG-reactive proteins within the purified prepa-
rations, none of which were present when a goat isotype control IgG column was used (Supplementary 
Figure 1). The immunoprecipitates were separated by SDS-PAGE, and the identity of the purified anti-
gens was determined by proteomic analysis using a publically available proteomic database derived from 
two M1 S. pyogenes genomes (SF370 and MGAS5005).
A total of 94 E-IVIG reactive antigens were recovered from the immunoprecipitates which included 
several major S. pyogenes vaccine candidates previously described in the literature (Table  1 and 
Supplementary Table 2). As in previous surface proteome studies, a number of secreted and classically 
cytoplasmic proteins were clearly present within the starting cell wall extracts11,12. Remarkably many such 
proteins were purified by E-IVIG immunoprecipitation, suggesting that these molecules are capable of 
generating a strong humoral immune response during S. pyogenes infection. Of the 94 proteins identified, 
only ten were recovered from all 20 isolates, suggesting that these antigens are reproducibly expressed 
by all four invasive serotypes selected for study, and share a high degree of sequence identity between 
serotypes. These conserved antigens included virulence factors (C5a peptidase13, and SpyAD14), lipo-
proteins (maltose/maltodextrin-binding protein, oligopeptide-binding protein and nucleoside-binding 
protein), other cell wall-attached, LPXTG motif-containing molecules (putative pullulanase) and a single, 
abundant cytoplasmic protein (Chaperone protein DnaK) previously shown to stimulate in vivo antibody 
production15. Two of the proteins had no attributed function despite their clear degree of conservation 
and propensity to generate a strong humoral immune response during S. pyogenes infection (hypothetical 
membrane associated protein and cell surface protein).
To ensure that recognition of these antigens was not limited to a single source of IVIG, E-IVIG was 
derived from two further commercial preparations (Intratect and Privigen) and used to immunoprecipi-
tate reactive antigens from two representative strains of each of the four S. pyogenes serotypes. Proteomic 
analysis identified the same panel of highly conserved antigens within the resulting immunoprecipitates, 
further implicating these molecules as important targets of adjunct IVIG therapy for invasive S. pyogenes 
infection (Supplementary Table 3).
E-IVIG promotes opsonophagocytic killing of S. pyogenes in vitro. To determine if the higher 
affinity of E-IVIG for S. pyogenes surface antigens resulted in increased anti-streptococcal activity, the 
ability of E-IVIG and IVIG to promote opsonophagocytosis and killing of M1 S. pyogenes (strain H364) 
was compared. At IgG concentrations ranging from 40 μ g/ml to 10 μ g/ml, the percentage of neutro-
phils containing internalised S. pyogenes was significantly higher in the E-IVIG group than in the IVIG 
group (Fig.  2A). These results were echoed in a classical Lancefield assay of opsonophagocytic killing, 
where concentrations in excess of 1 mg/ml IVIG are normally required to enhance bacterial killing8. 
Supplementation of human whole blood with 40 μ g/ml of E-IVIG was sufficient to increase opsono-
phagocytic killing by a factor of ten compared to supplementation with the same concentration of IVIG 
(Fig. 2B). Together these data suggest that purification of the S. pyogenes reactive IgG from IVIG results 
in a marked increase in opsonophagocytic killing through functional recognition of one or more sero-
type independent S. pyogenes surface antigens.
Passive immunisation with E-IVIG inhibits dissemination of S. pyogenes from an intramuscu-
lar focus of infection. To assess the efficacy of E-IVIG in vivo, two groups of age matched C57BL/6 
mice were passively immunised with E-IVIG or IVIG and challenged intramuscularly with 5 × 106 CFU 
of M1 S. pyogenes (strain H305). The mice were culled 24 h post infection and the degree of bacte-
rial dissemination was assessed by homogenisation of the organs and plating. Bacterial counts from 
the locally draining inguinal lymph node and blood of the E-IVIG group were significantly lower than 
those recovered from the IVIG group, consistent with an enhancement in bactericidal activity (Fig. 3). 
A similar trend was observed in the liver, although the difference was insufficient to achieve statistical 
significance. E-IVIG therapy had a limited effect on the bacterial burden at the site of infection, con-
sistent with data from previous studies where treatment with antibiotics, or antibiotics plus IVIG, failed 
to promote bacterial clearance at the site of infection, despite promoting clearance from the blood and 
organs8. Together the data suggest that purification of the S. pyogenes-reactive IgG from IVIG greatly 
enhances the anti-streptococcal activity of the reagent both in vitro and in vivo.
Discussion
Although IVIG is now widely advocated as an adjunctive treatment for clinical S. pyogenes infection, 
no studies have sought to characterise the repertoire of proteins recognised by the reagent. Our data 
demonstrate the full repertoire of proteinaceous surface antigens recognised by IVIG, and illustrate the 
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capability of the anti-streptococcal antibody present within the reagent to promote opsonophagocytic 
killing of S. pyogenes in vitro, and provide passive protection in vivo, during invasive infection.
In Europe and North America, approximately 70% of all invasive S. pyogenes infections are caused 
by the ten most prominent M types1,2, four of which were represented in this study. While M1 and M3 
remain the most common cause of invasive S. pyogenes infection, recent data suggest that has been an 
upsurge in invasive M89 infections over the past decade16,17. In this study E-IVIG was produced using 
serotype M1 cell wall extract, and a proteomic database derived from two M1 S. pyogenes genomes was 
used to identify the purified antigens. Of the 94 protein antigens isolated, only ten sequence-invariant 
antigens were identified from all 20 S. pyogenes strains selected for study. In addition to confirming that 
these antigens were expressed by four disparate S. pyogenes serotypes experimentally, the fidelity of the 
ten protein sequences was confirmed within all serotypes for which genome sequence data are currently 
available to ensure a high degree of conservation (data not shown). We considered the possibility that 
sequence variation and/or type-specific variation in gene content precluded proteomic identification of 
IVIG-reactive proteins from some isolates. However, with the exception of certain type-specific proteins 
such as the M protein and pilus, the core genomes of different S. pyogenes serotypes are largely conserved 
in sequence, and gene content18. Indeed, selective re-analysis of the purified immunoprecipitates using 
separate M3, M12 and M89 proteomic databases did not impact appreciably on our findings (data not 
shown). Therefore the ten highly conserved, invariant antigens identified herein may be of particular 
importance for the reported efficacy of adjunct IVIG therapy, and may warrant consideration as compo-
nents of an effective anti-S. pyogenes vaccine.
Interestingly, despite the use of pooled M1 cell wall extract for affinity purification of E-IVIG, and an 
M1 database for proteomic analysis of the resulting immunoprecipitates, the M protein was identified 
in 14/20 strains evaluated. The apparent absence of the M protein from the M89 preparations could be 
wholly attributed to substantial differences between the M1 and M89 protein sequences; and reanalysis 
of the M89 immunoprecipitate data using an emm89 sequence clearly identified M protein from all 
five strains selected for study (data not shown). Therefore, despite considerable variation between the 
Uniprot 
identifier Protein product
SEQUEST P-values 
(range) M1 M3 M12 M89 Total
C5AP_STRP1 C5a peptidase 1 × 10−30 − 7 × 10−10 5/5 5/5 5/5 5/5 20/20
100%
DNAK_STRP1 Chaperone protein DnaK 8 × 10−15 − 8 × 10−8 5/5 5/5 5/5 5/5 20/20
Q48Y96_STRP1 Maltose/maltodextrin-binding protein 2 × 10−16 − 3 × 10−10 5/5 5/5 5/5 5/5 20/20
Q490V0_STRP1 Oligopeptide-binding protein 1 × 10−30 − 2 × 10−10 5/5 5/5 5/5 5/5 20/20
Q491G2_STRP1 Nucleoside-binding protein 1 × 10−30 − 1 × 10−15 5/5 5/5 5/5 5/5 20/20
Q99XX8_STRP1 Putative pullulanase 2 × 10−14 − 6 × 10−8 5/5 5/5 5/5 5/5 20/20
Q99ZH4_STRP1 Nucleoside-binding protein 1 × 10−30 − 7 × 10−11 5/5 5/5 5/5 5/5 20/20
Q99ZW9_STRP1 Hypothetical membrane associated protein 1 × 10
−30 − 2 × 10−13 5/5 5/5 5/5 5/5 20/20
Q9A0C0_STRP1 Cell surface protein 7 × 10−14 − 3 × 10−7 5/5 5/5 5/5 5/5 20/20
Q9A1H3_STRP1 SpyAD 2 × 10−15 − 4 × 10−11 5/5 5/5 5/5 5/5 20/20
EFTS_STRP1 Elongation factor Ts 3 × 10−15 − 3 × 10−8 5/5 5/5 4/5 5/5 19/20
70-95%
MTSA_STRP1 Metal ABC transporter substrate-binding lipoprotein 1 × 10
−30 − 9 × 10−10 5/5 5/5 4/5 5/5 19/20
PGK_STRP1 Phosphoglycerate kinase 6 × 10−14 − 5 × 10−9 5/5 3/5 5/5 5/5 18/20
Q99YL6_STRP1 Putative uncharacterised protein 2 × 10−9 − 2 × 10−6 4/5 4/5 5/5 5/5 18/20
Q9A0C5_STRP1 Putative uncharacterised protein 1 × 10−10 − 6 × 10−5 5/5 3/5 5/5 5/5 18/20
TACY_STRP1 Streptolysin O 1 × 10−30 − 5 × 10−7 5/5 5/5 5/5 3/5 18/20
PEPDB_STRP1 Probable dipeptidase B 1 × 10−30 − 2 × 10−7 4/5 3/5 5/5 5/5 17/20
Q7DAN2_STRP1 Nicotine adenine dinucleotide glycohydrolase 8 × 10
−15 − 3 × 10−11 5/5 5/5 5/5 2/5 17/20
Q9A1G0_STRP1 Penicillin-binding protein 9 × 10−12 − 1 × 10−4 2/5 5/5 5/5 5/5 17/20
Q490K8_STRP1 SpyCEP 3 × 10−15 − 1 × 10−5 5/5 5/5 2/5 4/5 16/20
Q99XU2_STRP1 Periplasmic component of efflux system 3 × 10−13 − 9 × 10−9 5/5 3/5 3/5 5/5 16/20
Q48XJ9_STRP1 Sugar-binding protein 3 × 10−15 − 2 × 10−5 5/5 3/5 1/5 5/5 14/20
Q99XV0_STRP1 M protein 5 × 10−13 − 5 × 10−6 5/5 5/5 4/5 0/5 14/20
Table 1.  The S. pyogenes antigens purified by E-IVIG immunoprecipitation. Numbers represent the 
proportion of strains from which each target was identified. Targets identified from ≥ 70% of strains are 
displayed.
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different emm sequences, a substantial amount of cross reactive anti-M protein antibody was clearly pres-
ent within the affinity purified E-IVIG preparation. This finding supports the existence of cross protective 
epitopes within disparate M protein isoforms19.
Repeated exposure of the humoral immune system to a variety of common pathogens results in 
the accumulation of circulating antibodies with a diverse range of specificities. Affinity purification of 
anti-streptococcal antibodies from IVIG resulted in the generation of an antibody preparation with 
enhanced activity against S. pyogenes in vivo. While the breadth of protection may still be limited by 
serotype or strain specific differences in protein expression, E-IVIG may represent a more effective 
adjunct treatment for invasive S. pyogenes infection than the polyspecific IVIG that is currently employed 
clinically. It is possible that hyperencapsulation of S. pyogenes may impact negatively on the efficacy of 
therapeutic opsonic antibodies through masking of surface antigens, especially in strains that possess 
mutations in the global virulence regulator CovR/S20. However, IVIG was capable of promoting opsono-
phagocytic uptake of the hyperencapsulated covS mutant H39516, albeit at a reduced level (Fig. 1). This 
suggests that, while some of the epitopes targeted by IVIG may be shielded from antibody recognition 
by the capsule, a crucial subset remain exposed in hyperencapsulated isolates.
Although not intended to target secreted proteins, a number of extracellular toxins were purified from 
the cell wall extracts by E-IVIG immunoprecipitation, including streptolysin-O and the cysteine pro-
tease SpeB. Intriguingly, the repertoire of purified secreted proteins did not include any superantigens, 
which play a key role during invasive S. pyogenes infection and are strong targets of the human humoral 
immune response10,21. Thus further development of E-IVIG for S. pyogenes sepsis will have to address the 
possibility that the broadly acting anti-superantigen activity of IVIG may not be maintained following 
anti-streptococcal antibody enrichment. Furthermore, any pre-clinical evaluation of E-IVIG will require 
rigorous screening to ensure the purity of the antibody preparation and to rule out any unforeseen tox-
icity resulting from the carryover of bacterial products. Nonetheless, in light of the shortage of human 
immunoglobulin, it may be prudent to determine whether therapeutic antibodies against a wider range 
of pathogens could be sequentially isolated from a single IVIG preparation using multiple rounds of 
affinity purification. Such targeted reagents may prove valuable for the adjunct treatment of a wide range 
of common antimicrobial-resistant pathogens. Indeed while here we have applied immunoprecipitation 
to S. pyogenes, published reports and our own unpublished data suggest that the technique could equally 
Figure 2. E-IVIG promotes opsonophagocytic killing of S. pyogenes in vitro. (a) FITC labelled M1 
S. pyogenes cells (strain H364) were opsonised with doubling dilutions of E-IVIG (white bars) or IVIG 
(black bars) prior to incubation with freshly isolated human neutrophils. Results from three independent 
experiments are expressed as percentage of FITC+ neutrophils (mean ± SD) after a 30 min co-incubation. 
n = 3, two-tailed t-test: p = 0.002 (40 μ g/ml); p < 0.0001 (20 μ g/ml); p = 0.0001 (10 μ g/ml). (b) Whole blood 
from healthy donors was supplemented with 40 μ g/ml of E-IVIG (open triangles) or IVIG (closed squares) 
prior to inoculation with ~20 CFU of M1 S. pyogenes (strain H364). Results are expressed as multiplication 
factors (median and range). n = 9, two-tailed Mann-Whitney U: p = 0.0005. ND: Not Detected.
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be applied to other Gram positive bacteria such as Staphylococcus aureus and Enterococcus spp. where 
clearance is mediated through similar processes6,7,22.
As a pooled preparation of immunoglobulin from normal donor blood, IVIG is an obvious but hith-
erto unevaluated reagent for the systematic identification of the antigens recognised by the humoral 
immune response of a healthy human population. Previous studies have attempted to characterise the 
streptococcal antigens targeted by the human antibody response, however the results may have been 
influenced by the use of non-native protein preparations and/or serum of unknown protective activity, 
which is often employed for screening target antigens12,23–25. The data in this study identify for the first 
time a core list of highly conserved S. pyogenes antigens against which protective humoral immunity is 
directed. The findings enhance our understanding of population immunity to S. pyogenes as a whole, and 
may have implications for both passive and active vaccination.
Materials and Methods
Bacterial strains and growth conditions. The S. pyogenes isolates used are listed in Supplementary 
Table 1 and were routinely cultured on Columbia horse blood agar (CBA) or in Todd-Hewitt broth 
(THB) at 37 °C in 5% CO2.
Preparation of streptococcal cell wall extracts and immunoblotting. Streptococcal cell wall 
extracts were isolated as previously described26. Briefly, overnight S. pyogenes cultures were diluted 1:10 
in fresh THB and grown to an A600 of 0.4–0.8. The cells were pelleted and resuspended in 1/50th volume 
of 10 mM Tris-HCl (pH 8.0) containing 30% raffinose, 100 U/ml mutanolysin, 1 mg/ml lysozyme and 
10% Protease Inhibitor Cocktail Set III (Calbiochem), and incubated for 3 h at 37 °C with occasional 
inversion. The cells were pelleted and the supernatant (cell wall extract) was dialysed into PBS over-
night and concentrated by centrifugation (10,000 MWCO). For immunoblotting, proteins were separated 
on 7% tris-acetate (TA) gels (Invitrogen) and transferred to Hybond LFP membranes (GE Healthcare). 
Figure 3. Passive immunisation with E-IVIG inhibits dissemination of S. pyogenes from an 
intramuscular focus of infection. Two groups of eight age matched C57BL/6 mice were pre-treated with 
800 μ g of E-IVIG (open triangles) or IVIG (closed squares) and infected intramuscularly with 5 × 106 CFU 
of M1 S. pyogenes (strain H305). Solid lines indicate the median CFU recovered from (a) the site of original 
infection, (b) ipsilateral draining lymph node, (c) blood and (d) liver 24 h post-infection. n = 8, two-tailed 
Mann-Whitney U: p = 0.0037 (node); p = 0.0325 (blood). ND: Not Detected.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:15825 | DOi: 10.1038/srep15825
Membranes were blocked with 5% skimmed milk prior to the addition of 4 μ g/ml IVIG (Endobulin®, 
Baxter). Bound antibodies were detected using a 1:80,000 dilution of HRP-conjugated goat anti human 
IgG (Sigma-Aldrich) and the ECL prime detection system (GE Healthcare).
Affinity purification of E-IVIG and immunoprecipitation of reactive streptococcal surface anti-
gens. Pooled serotype M1 cell wall extract was dialysed into coupling buffer (0.1 M sodium bicar-
bonate, 0.5 M sodium chloride, pH 8.3) overnight and coupled to cyanogen bromide (CNBr) activated 
agarose at a concentration of ~1 mg/ml according to the manufacturer’s instructions (Sigma-Aldrich). 
Briefly, lyophilised CNBr-activated agarose was swollen in cold 1 mM HCl (200 ml/g dry gel), pipetted 
into a 5 ml column and washed sequentially with ten column volumes of distilled water and five column 
volumes of coupling buffer. The dialysed cell wall extract was immediately added and incubated with 
the swollen resin overnight at 4 °C. The resin was washed extensively with coupling buffer and incubated 
with two column volumes of 0.2 M glycine at RT for 2 h with gentle agitation. The resin was washed 
sequentially with ten column volumes of coupling buffer and ten column volumes of sodium acetate 
buffer (0.1 M anhydrous sodium acetate, 0.5 M sodium chloride, pH 4). This high/low pH wash cycle was 
repeated five times and the resulting affinity purification column was equilibrated into PBS supplemented 
with 0.1% sodium azide. For affinity purification, the resin was incubated with 5 ml of 5 mg/ml IVIG for 
2 h at RT and washed extensively with PBS. Bound antibody was eluted into 1 ml aliquots of 1 M acetic 
acid and immediately neutralised using an equal volume of 3 M Tris-HCl (pH 8.8). Eluted fractions (con-
taining the E-IVIG) were pooled, dialysed into PBS and concentrated. E-IVIG was stored in 0.1% sodium 
azide at 4 °C until required. For immunoprecipitation, E-IVIG or goat isotype control IgG (Abcam) was 
coupled to CNBr-activated agarose at a concentration of ~1 mg/ml, and incubated with 2 ml aliquots of 
concentrated cell wall extract. The resin was washed extensively and the bound antigens were eluted, 
dialysed and concentrated as outlined above. For comparative immunoprecipitation experiments, addi-
tional E-IVIG preparations were prepared from Intratect® (Biotest) and Privigen® (CSL Behring) IVIG.
Analysis of E-IVIG by ELISA. To compare binding of E-IVIG and IVIG, 96 well plates were coated 
with 1 μ g/well of cell wall extract and incubated with 2.5 mg/ml of antibody. Bound antibodies were 
detected using a 1: 80,000 dilution of HRP-conjugated goat anti-human IgG and 50 μ l/well tetramethylb-
enzidine. The detection reaction was stopped through the addition of 50 μ l of 1 M H2SO4 and the absorb-
ance at 450 nm read using a μ Quant universal microplate spectrophotometer (Bio-tek instruments).
Opsonophagocytic uptake and killing assays. Human neutrophil opsonophagocytosis assays were 
performed using normal donor neutrophils obtained with informed consent from a subcollection of the 
Imperial College Tissue Bank and FITC-labelled S. pyogenes as previously described27. Briefly, bacterial 
cells from a 5 ml overnight culture were pelleted, washed and incubated in 500 μ l of 20 μ g/ml FITC in 
0.1 M sodium carbonate buffer (pH 9) for 30 min at 37 °C. The cells were washed twice and resuspended 
to an A600 of 0.35 in PBS and incubated with an appropriate concentration of E-IVIG, IVIG or PBS at 
37 °C for 30 min with agitation. Neutrophils were purified from heparinised whole blood that was com-
bined 1:1 with 3% dextran (MW > 100,000) in 0.9% saline and allowed to separate on ice for 30 min. The 
leukocytes present in the supernatant layer were pelleted and resuspended in one volume of 0.9% saline. 
Neutrophils were then purified by Ficoll-layering as described previously28. Opsonophagocytosis assays 
were performed in 1 ml reaction volumes containing 100 μ l of resuspended bacteria and 1 × 106 neutro-
phils. After a 30 min co-incubation, the S. pyogenes/neutrophil suspension was combined 1:1 with 0.02% 
EDTA in PBS and, immediately prior to analysis, the extracellular fluorescence was quenched through 
addition of one volume of trypan blue. Results are expressed as the percentage of neutrophils containing 
FITC+ bacteria as determined by flow cytometry. The strains selected were all isolated from invasive 
disease or toxic shock cases (Supplementary table 1). Whole blood opsonophagocytic killing (Lancefield) 
assays were performed under standard conditions using whole blood from three healthy human donors 
supplemented with 40 μ g/ml of IVIG or E-IVIG and approximately 20 CFU of M1 S. pyogenes (strain 
H364) using a standard method8,29,30. Results from nine independent reactions were expressed as the 
bacterial multiplication factor following 3 h incubation at 37 °C with gentle agitation.
Proteomic analysis. Immunoprecipitated antigens were separated on 7% TA gels and subjected to 
in gel trypsin digest and subsequent liquid chromatography-tandem mass spectrometry as previously 
described31. Proteins were identified using a publically available proteome for serotype M1 S. pyogenes 
(Uniprot, CP000017)32,33; and correlation of the MS/MS peptide data with the in silico trypsin fragmen-
tation patterns predicted using BioWorks 3.3 and the SEQUEST algorithm (Thermo Scientific). Peptides 
generating ions of 200–2000 amu, with a cross correlation score >1.5, 2.0, or 2.5 (where z = 1, 2 or 3 
respectively) and a p < 0.01 were mapped onto the S. pyogenes proteome. Proteins that contained two 
or more of the identified peptides were selected for further analysis. The protein probability for each 
selected protein was calculated using the SEQUEST algorithm and reported as a range of up to 20 values 
derived independently from analysis of proteins from each of the strains examined.
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Passive immunisation. 5–6 week old female C57BL/6 mice were passively immunised with 800 μ g 
of E-IVIG or IVIG in 100 μ l of PBS by intraperitoneal injection. 16 h after IgG administration, the mice 
were challenged intramuscularly with 5 × 106 CFU of M1 S. pyogenes (Strain H305 which has been used 
previously in IVIG protection studies8). After 24 h, the mice were culled, the blood and organs were 
removed and bacterial loads at the infection site and the degree of dissemination were assessed by plating 
serial dilutions of each organ homogenate onto CBA. All animal procedures were approved by the local 
ethical review process at Imperial College London and conducted in accordance with the relevant, UK 
Home Office approved, project license.
Statistical analysis. Data are expressed as mean and standard deviation (bar charts and line graphs) 
or median and range (scatter plots) and analysed using the two-tailed student’s t-test or two-tailed 
Mann-Whitney U where appropriate. Statistical significance was accepted where *p < 0.05. Curve fits 
were calculated by non-linear regression (GraphPad Prism).
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